Cetera Investment Advisers Sells 13,326 Shares of Haleon PLC Sponsored ADR $HLN

Cetera Investment Advisers cut its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 8.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 151,064 shares of the company’s stock after selling 13,326 shares during the period. Cetera Investment Advisers’ holdings in Haleon were worth $1,567,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in HLN. Private Trust Co. NA boosted its holdings in Haleon by 13.3% in the 2nd quarter. Private Trust Co. NA now owns 8,794 shares of the company’s stock valued at $91,000 after purchasing an additional 1,032 shares during the period. Allspring Global Investments Holdings LLC grew its position in Haleon by 4.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 31,423 shares of the company’s stock worth $321,000 after acquiring an additional 1,200 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in shares of Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after purchasing an additional 1,203 shares during the last quarter. First Horizon Advisors Inc. grew its holdings in Haleon by 8.0% in the 2nd quarter. First Horizon Advisors Inc. now owns 17,549 shares of the company’s stock worth $182,000 after acquiring an additional 1,302 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in Haleon by 5.9% during the 2nd quarter. GAMMA Investing LLC now owns 23,401 shares of the company’s stock valued at $243,000 after purchasing an additional 1,306 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on HLN shares. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research report on Wednesday, October 8th. Barclays lowered Haleon from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, September 16th. Finally, The Goldman Sachs Group raised shares of Haleon from a “neutral” rating to a “buy” rating in a report on Wednesday, September 10th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $12.33.

Haleon Price Performance

NYSE HLN opened at $9.81 on Tuesday. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. Haleon PLC Sponsored ADR has a 52 week low of $8.71 and a 52 week high of $11.42. The firm has a market capitalization of $43.66 billion, a P/E ratio of 25.14 and a beta of 0.20. The company has a 50-day moving average price of $9.31 and a 200-day moving average price of $9.84.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.